Advertisement

Topics

Extended Brillinta Treatment Reduces CV Death Risk by 29 Percent in Patients With Heart Attack History

11:22 EDT 24 Aug 2017 | Drug Discovery Development

The latest results highlight a potential protective CV benefit associated with longer-term treatment.
Contributed Author: 

Original Article: Extended Brillinta Treatment Reduces CV Death Risk by 29 Percent in Patients With Heart Attack History

NEXT ARTICLE

More From BioPortfolio on "Extended Brillinta Treatment Reduces CV Death Risk by 29 Percent in Patients With Heart Attack History"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...